COVID-19 Research

Wistar researchers in the Vaccine & Immunotherapy Center continue their concerted efforts to develop additional preventative and drug discovery approaches that could complement the existing vaccines and will add more tools to our preparedness resources, and to unravel the viral mechanisms of disease. The technologies under development are also being tested against some of the new viral variants.

Collaboration Advances DNA-delivered Antibodies to Prevent COVID-19

New synthetic nucleic acid approach seeks to use the body as the machinery for production of its own targeted protective antibodies.

PRESS RELEASE

The Wistar Institute Receives $4 Million in Funding From the Commonwealth of Pennsylvania to Advance COVID-19 Research, Address COVID-19 Risk on Vulnerable Populations, and Assess Pandemic Preparedness

PRESS RELEASE

DARPA and JPEO-CBRND Award $37.6M to The Wistar Institute and Collaborators at INOVIO, AstraZeneca, Penn, & Indiana University to Develop Innovative COVID-19 Treatment

COVID-19 Advisory

Wistar continues to follow the Centers for Disease Control and Prevention guidelines.

Wistar Scientists Behind the Next Wave of COVID-19 Vaccines

A new COVID-19 vaccine developed by Wistar scientists uses immune focusing and self-assembling nanoparticles to elicit higher levels of neutralizing antibodies. Animal studies show it offers stronger, broader and more durable protection from a single, lower dose — including protection from variants.